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surgical risk assessment.(3) In the 2017 ACC/AHA guidelines 
TAVI carries a class IA recommendation for high risk patients 
and a Class IIa recommendation for intermediate surgical risk 
patients.(4)
TAVI has successfully been implemented in South Africa, with 
the first TAVI procedure performed in October 2009(5) and 
local guidelines were published by the South African Society of 
Cardiovascular Intervention and the Society of Cardiothoracic 
Surgeons of South Africa.(6) The South African SHARE-TAVI 
registry was established in October 2014. This registry is a first 
of its kind in South Africa and aims to include all patients 
referred for TAVI. Eleven centres in South Africa are recruiting 
patients. Outcomes reported are as per the VARC-2 (Valve 
Academic Research Consortium-2) consensus document pub-
lished in 2012.(7) One of these end points is the development 
of conduction defects post TAVI. This is currently the most 
INTRODUCTION
The first in vivo transcatheter aortic valve implantation (TAVI) 
was performed by Alain Cribier in Rouen in 2002.(1) Initially 
TAVI was indicated for patients with symptomatic severe aortic 
stenosis (AS) with an absolute contraindication to surgical 
aortic valve replacement and high surgical risk assessment. In 
the interim data in intermediate risk patients have influenced 
the current guidelines.(2,3) In the 2017 ESC guidelines TAVI car-
ries a class IB recommendation for patients with an increased 
ABSTRACT
Background: One of the most common complications 
post transcatheter aortic valve implantation (TAVI) is 
the development of heart block requiring permanent 
pacemaker implantation (PPM). The incidence of PPM 
in international registries ranges from 13% - 17.5%.  
Methods: The aim of this observational study was to 
report the PPM rate in the SHARE-TAVI registry and 
determine the clinical, electrocardiographic and pro-
cedural predictors of PPM as well as the effect of PPM 
on clinical outcomes. 
Results: Three hundred and fi ve subjects were analysed. 
The PPM rate was 9%. Third degree atrioventricular 
block at the time of implant was the most common 
indication for PPM. Self-expanding valves (PPM rate 
14% vs. 6% for balloon-expandable valves, p=0.02) were 
correlated with the need for PPM. Baseline ECG pre-
dictors of PPM were axis deviation, QRS duration and 
conduction delay, most notably a pre-existing right 
bundle branch block (OR 15.88, p<0.01). PPM infl u-
enced functional class at 30 days, but not the need for 
repeat hospitalisation or mortality at 30-day and 1-year 
follow-up. 
Conclusions: A PPM rate lower than that reported in 
large international registries was found. Predictors of 
PPM and the infl uence of PPM on outcomes were simi-
lar to those reported in the international data.   
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common complication of the procedure, occurring in as much 
as 34.6% of patients at discharge.(8) Furthermore, improve-
ments in TAVI technology, together with the increasing 
experience of operators/centres, have resulted in a major 
reduction in peri-procedural complications, yet the incidence of 
conduction disturbances leading to permanent pacemaker 
implantation (PPM) has remained relatively high.(9) It is therefore 
important to understand and limit such TAVI-related compli-
cations because TAVI is set to expand to patients at interme-
diate and low surgical risk among whom the detrimental 
consequences of conduction disturbances and long-term right 
ventricular pacing may be even more pronounced.(10) 
METHODS
Study Rationale
The aim of this observational study was to report the PPM rate 
in the SHARE-TAVI registry and determine the clinical, electro-
cardiographic and procedural predictors of PPM as well as 
the clinical outcomes of the development of a conduction 
disturbance. 
Study Population
The SHARE-TAVI registry prospectively collected detailed data 
on more than 96% of all TAVI implants in South Africa from 
November 2014 until the present. The registry has ethics 
approval from both the ethics committees of the University of 
Stellenbosch (HREC Ref No: N14/06/073) and the University 
of Cape Town. Data is entered by the treating physician into a 
protected and de-identified database. 
To ensure accuracy, the investigators reviewed all case notes 
and electrocardiograms and verified all parameters entered into 
the database. For logistical reasons, only data from centres 
performing more than 10 procedures per year were analysed. 
Three hundred and five patients were analysed for this study 
of which 197 had follow up data available up to 1 year. Patients 
with pre-existing pacemaker implants were excluded.
Data Collection
Multiple clinical echocardiographic baseline parameters were 
extracted from the registry [age, sex, site performed (state or 
private sector), baseline creatinine, aortic valve gradients and 
area, pulmonary pressures, valve type implanted, surgical risk 
scores and access site]. Electrocardiogram (ECG) parameters 
pre- and post-implant (rate, rhythm, PR interval, QRS width, 
QRS axis, evidence of conduction disturbance) were extracted 
from the registry and independently reviewed by the principal 
investigator by means of individual folder review. The aortic 
valve annulus diameter as determined by computed tomo-
graphy (CT) was divided by the diameter of the implanted 
valve at the annulus as specified by the manufacturers to deter-
mine the degree of oversizing. It was ascertained whether a 
pacemaker was inserted and when it was inserted in temporal 
relation to the procedure. The indication for PPM in each case 
was assessed according to the ESC guideline.(11) 
Statistical analysis
Comparisons of continuous measurements between groups 
were tested using one-way ANOVA. In all cases assumptions 
of normality were assessed by inspecting normal probability 
plots. In cases where the assumptions were suspect, Mann-
Whitney U tests were also done, but were in all cases found to 
give the same results as the ANOVA F-tests. Thus, only the 
latter were reported.
For pre- post comparisons, mixed model ANOVAs were used 
with time (pre, post) as fixed effect, and the patients as ran-
dom effect.
Categorical variables were compared using the cross tabulation 
and the Fisher exact test. For pre/post testing of categorical 
variables, the Stewart-Maxwell Chi-square test was used.
Receiver Operating Curve (ROC) analyses were conducted to 




Baseline characteristics and procedural information is displayed 
in Table I. The PPM rate was 9% in the cohort studied. All these 
parameters were correlated with the need for PPM. Predictors 
of PPM were baseline creatinine, dyspnoea grade and type of 
valve implanted [balloon-expandable (BE) vs. self-expanding 
(SE)] (Table II).
Procedural characteristics
The degree of oversizing was determined for those patients 
that had CT scan parameters entered into the registry. The 
degree of oversizing was determined as described in Methods. 
The degree of oversizing was higher for SE valves (1.22 vs. 1.11 
for BE valves). The degree of oversizing was also associated 
with the need for PPM (Figure 1). The effect of valve type was 
also investigated, but did not influence the difference as seen in 
Figure 1 (interaction p=0.29) (Figure 2).
ECG Parameters pre- and post-TAVI
Baseline ECG parameters and immediate post TAVI parameters 
are described in Table III. The most notable changes were the 
development of heart block. There was a small but statistically 
significant prolongation of the average PR interval of the pre- 
and post-TAVI groups (from 184ms - 191ms), however only 19 
patients (6%) progressed to a PR interval of more than 200ms. 
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Further significant changes were the development of a new left 
bundle branch block (LBBB) and a prolongation of the QRS 
duration post-TAVI. 
Indications and timing of PPM
The incidence of PPM was 9%. This equated to 27 pacemaker 
implantations, 26 of which had a Class I indication for PPM 
according to the ESC guidelines.(11) The patient with no Class I 
indication for PPM had a pacemaker implanted because of 
progressive PR interval prolongation, from 210ms prior to 
TABLE I: Baseline and Procedural Characteristics (n=305).
Age (mean) 80 years (SD 7.85 years)









Creatinine (mean) 100mmol/L (SD 38mmol/L)
Echocardiographic parameters 
(mean)
Mean Gradient (mmHg) 53mmHg (SD 19mmHg)
Peak Velocity (m/s) 4.31m/s (SD 0.72m/s)
Aortic valve area (mean) 0.7cm2 (SD 0.17cm2)




Log Euro  Score % (mean) 23.5% (SD 16.1%)








TABLE II: Clinical and Procedural Predictors of PPM.
Parameters at implant of the TAVI valve (mean) PPM No PPM p-value (ANOVA F-test
Age (years) 78.9 80.4 0.32
Creatinine (umol/L) 119 99 0.02
Mean Aortic Valve Gradient (mmHg) 49 53 0.22
Peak Aortic Valve Velocity (m/s) 4.34 4.30 0.88
Aortic Valve Area (cm2) 0.7 0.75 0.19
Aortic Valve Annulus Diameter (mm) 23.2 22.6 0.38
Pulmonary Artery Systolic Pressure (mmHg) 41.7 49.8 0.08
Log Euro score (%) 27.6 23.3 0.26
STS score (%) 4.7 6.8 0.20
NYHA grade dyspnoea 2.95 2.66 0.03
History of Syncope (%) 31 25 0.56
Frailty (%) 71 72 1.00
Porcelain Aorta (%) 17 21 1.00


























F(1,246) = 16.324, p<0.01















TAVI, to 320ms immediately post TAVI, and 360ms at day 3 
post implant. 17 of the patients developed the indication for 
PPM immediately post TAVI. For the remaining 10 patients 
there was an average delay of 5.8 days until the indication for 
PPM occurred. In these patients an average of prolongation in 
QRS duration of 20ms was demonstrated. Seven of these 
patients had variable changes in an ECG parameter from their 
baseline ECG. Interestingly 2 cases developed their indication 
for PPM on days 10 and 11 respectively. 
ECG predictors of PPM
Pre-existing arrhythmia, pre-TAVI heart rate and presence of 
a first degree heart block did not predict the development of 
an indication for PPM. The parameters that were statistically 
significant predictors for the development of indications for 
PPM were a prolonged QRS duration, and pre-existing right 
bundle branch block (RBBB). 
A QRS of less than 103ms provided a negative predictive value 
of 96%, with a ROC curve AUC of 0.70 (Figure 3). The positive 
predictive value however was only 20%. The mean delta QRS 
TABLE III: ECG parameters.
Pre-TAVI (n = 292)
Post–TAVI (n =271) 
(immediately post TAVI)
p-value
Sinus Rhythm (%) 83% 80% <0.01 
Arrhythmias (%) 17% 20% 0.03
Atrial fi brillation 17% 13%
Atrial fl utter 0% 1%
Other 0% 0%
Heart Block (AV) 0% 6%
Rate mean (bpm) 72 (SD 14) 72 (SD 16) 0.64





North West 1% 1%
QRS duration mean (ms) 104 (SD 24) 110 (SD 27) <0.01
Conduction delays (incidence) 0.01
LBBB 10% 24%
RBBB 5% 7%
Left Anterior Hemiblock (LAHB) 9% 8%
Left Posterior Hemiblock (LPHB) 0% 1%
Non-specifi c intraventricular (NSIVC) 0% 0%
 
PPM
FIGURE 2: Degree of oversizing and need for PPM 































F(1,246) = 1.120, p=0.29
Vertical bars denote 0.95 confidence intervals
Yes
BE            SE
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(difference between pre- and post-TAVI QRS duration) was 20 
milliseconds for the 10 patients who required PPM and did not 
develop an immediate third degree AV block post TAVI, com-
pared to 11ms mean delta QRS for those that did not require 
PPM (p=0.06). 
The strongest predictor was the presence of a pre-existing 
RBBB (Odds Ratio 15.88) (Figure 4). 
Post procedural predictors were interpreted speculatively as 
only 10 of the 27 patients who did have a PPM did not develop 
their heart block immediately post TAVI. Of these 10 patients, 
7 had a change in their ECG parameters, prior to developing 
heart block. These changes included a prolongation in PR 
interval, the development of a new axis deviation or a new 
bundle branch block. 
PPM and clinical outcomes
At 30 days of follow up there was no statistically significant 
difference in mortality or rehospitalisation in the PPM vs. non 
PPM groups. A larger proportion of patients had NYHA III 
dyspnoea in the PPM group vs. the non-PPM group (27% vs. 
5%, p=0.05) At 1 year there was no difference in mortality or 
rehospitalisation between the groups. The difference in func-
tional class was no longer significant PPM prolonged the pro-
cedure as expected. PPM had no significant difference on the 
duration of time spent in the ICU or in hospital (Table IV).
DISCUSSION
We report from the SHARE-TAVI Registry, the first data on 
pacemaker implantation post TAVI in a resource limited 
environment and could show lower rates of PPM implantation 
than in other international studies.
Conduction Disturbances after TAVI 
The Atrioventricular (AV) node and the left bundle are in close 
relation with the aortic valve. This may explain the develop-
ment of conduction abnormalities post TAVI implant (Figure 5). 
Necropsy studies have found that interaction between the 
newly implanted TAVI valve and the conduction system may 
lead to a direct mechanical insult to the conduction system 
associated with various degrees of oedema, haematoma, and 
ischaemia.(12)
New LBBB is the most commonly described conduction dis-
turbance due to TAVI.(13) The aforementioned was also found 
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Number of cases = 289
QRS duration ms(pre) = 103            
AUC = 0.70 (0.59 - 0.82)




























Categorised histogram: ICD = RBBB x PPM yes/no
Chi-square (df=1) = 28.03, p = 0.00000 Fisher Exact p = p<0.01









TABLE IV: Duration of ICU and ward stay 








Duration of ICU 
stay (days)
1.87 2.62 0.07















in this study with the incidence of LBBB increasing from 10% 
pre-procedurally to 24% post-procedurally. A statistically signi-
ficant prolongation of the QRS duration was found in the 
cohort. 
High degree AV block and PPM after TAVI
A meta-analysis published in 2013 of 49 studies and registries 
comprising 16 063 patients demonstrated a pooled PPM rate 
of 13%.(14) A more recent meta-analysis published in 2016 
showed a PPM rate of 13% in 20 287 patients (15). The German 
Aortic Valve Registry (GARY) published data in 2015 of 15 964 
patients who received TAVI between 2011 and 2013 and 
reported a PPM rate of 17.5%.(16) A significantly lower PPM 
rate of 9% was found in this study. The exact explanation for 
this low rate is not known, but 2 important factors should be 
noted: because of the small number of cases, every patient’s 
data and ECG could be verified by the principal investigator, 
making our data very robust. Secondly, we could show that opera-
tors adhered strictly to established indications for pacing.(11) 
It is well described that PPM rates vary according to valve type. 
The PPM rate has been shown to be 5 times more frequent in 
patients receiving a SE valve (25% - 28%) compared to those 
who received a BE valve (5% - 7%).(17) This correlates with our 
findings in which self-expanding valves had a 14% incidence of 
PPM vs. a 6% incidence of PPM for balloon expanding valves. 
Predictors of the development of high degree AV block 
and PPM
Clinical Predictors
Clinical characteristics described in the literature to be 
associated with a higher rate of PPM are age greater than 75 
years,(18) male sex(19) and a higher surgical risk stratification score 
(EuroSCORE).(20) These factors did not correlate with PPM 
in our cohort, however baseline creatinine and dyspnoea grade 
did. It is hard to explain this other than the chance and variable 
reporting by operators. 
ECG Predictors
Pre- and post-procedural evidence of conduction abnormalities 
on the electrocardiogram (ECG) have been associated with 
PPM. The most commonly described association with PPM in 
the literature is the presence of pre-procedural RBBB.(21–26) 
Furthermore a first degree atrioventricular block,(22,23) a left axis 
deviation,(27) prolonged QRS duration(20) and atrial f ibrilla-
tion(25,28) are ECG abnormalities associated with PPM. Our 
study revealed that a prolonged QRS duration and a pre-
existing RBBB were predictors of PPM. The longer QRS dura-
tion may be indicative of pre-existing infra-nodal conduction 
disease and a RBBB would leave the patient dependent on the 
at-risk left bundle. Our findings therefore correlate well with 
the proposed pathophysiology of heart block post TAVI (see 
Figure 5). First degree AV block, QRS axis deviation and pre-
procedural arrhythmia did not correlate with PPM.
Procedural Predictors
Degree of oversizing has been associated with a higher PPM 
rate.(28) This correlated with the need for PPM in our study but 
was no longer significant when assessed within individual valve 
types (BE and SE) (Figure 2). Height of implantation may have 
been a better parameter to evaluate but this analysis was not 
possible in the current study. 
FIGURE 5: Graphic representation of the relationship of the TAVI valve to the aortic valve and conduction system.
*nIVS = interventricular septum, NCC = non-coronary leaflet, RCC = right coronary leaflet, LCC = left coronary leaflet, TV = tricuspid value, 















Reported post procedural ECG changes associated with PPM 
are the development of a new left bundle branch block 
(LBBB),(27,29) and an increase in QRS duration from baseline.(30) 
It has further been shown that delta QRS duration (i.e., QRS 
duration after TAVI minus QRS duration before TAVI) of 38 
milliseconds or more is predictive of PPM.(28) In this study a 
small number of patients (10) did not develop heart block imme-
diately. A mean delta QRS of 20ms was found in these patients. 
Of these, 7 did have a change from their baseline ECG. These 
changes were variable in each of the 7 patients. Because of the 
small numbers, we cannot make meaningful recommendations 
on a cut-off value that can be used in clinical practise. 
Timing of PPM
TAVI-induced high degree AV block occurs mainly in the peri-
procedural setting, 60% - 96% of these events were recorded 
within 24 hours of TAVI(31) Approximately 2% - 7% of patients 
(representing up to 30% of all patients with high degree AV 
block) experienced delayed high degree AV block more than 
48 hours after TAVI (31,32). PPM is mainly performed within 7 
days of the procedure (85% - 90% of cases), with a median time 
from TAVI to PPM of 3 days.(33) In this study the majority of 
patients (63%) developed an immediate indication for PPM. 
The remainder developed their indication an average of 5.8 
days after TAVI. One patient developed an indication for PPM 
11 days after TAVI. 
The ESC pacing guidelines recommend a period of clinical 
observation and electrocardiographic monitoring for up to 7 
days before PPM in patients with high degree AV block to 
determine whether rhythm disturbances after TAVI are tran-
sient or permanent (Class I, Level of Evidence C).(11) This is 
however not what is practised as more than 50% of pace-
makers are implanted in the first 3 days post TAVI.(33) The 
prolonged waiting period may incur risk associated with 
prolonged temporary pacing and its resultant immobility. As the 
indications for TAVI implantation expand this will no doubt 
become a difficult clinical management question. 
Impact of PPM on outcomes
Reporting on the impact of PPM on morbidity and mortality 
has shown variable results. There is evidence that PPM after 
TAVI has been linked to and increased risk of recurrent hospi-
talisations for cardiovascular reasons.(34) Fadahunsi, et al., in a 
cohort of 9 785 patients, demonstrated that PPM negatively 
affected survival (31% higher relative risk for 1-year mortality) 
and heart failure admissions (33% increased relative risk).(33) A 
cohort of 1 973 patients in the PARTNER trial showed a trend 
toward a reduction in 1-year survival after PPM, this was, how-
ever not statistically significant.(35) 
In a meta-analysis published by Regueiro, et al., the authors 
demonstrated a trend toward a reduction of cardiovascular 
deaths in those who received PPM post TAV.I(36) 
In our study no difference in mortality or rehospitalisation was 
seen at 30-days and 1-year of follow-up. The UK TAVI registry 
analysed 6 420 patients and found a 1-year survival of 
83.4%, compared to our cohort, where the 1-year survival was 
89.5%.(37) Lower PPM rate may in theory predispose to 
increased sudden cardiac death in those who develop heart 
block late. Our mortality data suggests that our significantly 
lower PPM rate had no deleterious impact on long term sur-
vival. There was a trend towards a reduction in functional class 
at 30-days, but not at 1-year (although 1-year follow-up 
numbers were low).
Limitations
For logistical reasons, this study includes the results from the 
higher volume centres only. Although it represents the vast 
majority of cases done in this time period, it may not be 
representative of the whole country. The total number of cases 
included is modest relative to international registries but still 
enabled us to make significant deductions on a number of 
parameters.
CONCLUSION
This is the first data from a resource limited setting describing 
the incidence and predictors of PPM after TAVI. The data was 
generated from a combination of state and private healthcare 
patients. 
The clinical and ECG predictors for PPM were similar to those 
that have been well described in large studies, with self-
expanding valves and a pre-existing RBBB being the strongest 
predictors of PPM. 
For the local TAVI operator this study shows that extra care 
should be taken in those with pre-existing QRS prolongation or 
a RBBB and those who develop ECG changes post TAVI should 
be observed vigilantly for an indication for PPM. QRS duration 
of less than 103ms also provides a fair negative predictive value 
for PPM. 
Reassuringly the PPM rate was significantly lower than that 
described in larger trials and registries from the developed 
world, without a negative effect on outcomes. The reasons for 
this may be multifactorial, it must be noted that TAVIs are 
implanted in a resource limited environment with strict adher-
ence to guidelines. 
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